Premium
Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
Author(s) -
Katzenschlager Regina,
Jackson Michael J.,
Rose Sarah,
Stockwell Kim,
TayaraniBinazir Kayhan A.,
Zubair Mohammed,
Smith Lance A.,
Jenner Peter,
Lees Andrew J.
Publication year - 2007
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.21256
Subject(s) - benserazide , mptp , marmoset , levodopa , parkinson's disease , pharmacology , medicine , dyskinesia , endocrinology , disease , biology , paleontology
The neuropeptide melanocyte‐inhibiting factor (MIF) or L ‐propyl‐ L ‐leucyl‐glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N ‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD. © 2007 Movement Disorder Society